Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
PET imaging of pathological tau correlates more closely with Alzheimer’s disease–related cognitive impairment than does imaging of β-amyloid.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These previous studies suggest that CSF tau biomarkers and Tau PET reflect different aspects of tau pathology and may become abnormal at different stages of the disease.”
From Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer's disease (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated tau PET binding in both medial temporal lobe structures and the neocortex is strongly associated with positive amyloid PET scans and with clinical impairment across the normal aging to dementia clinical spectrum [82,130–141].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the limited data currently available, tau PET ligand binding is linearly correlated with elevated CSF P-tau [82,83,115]; however, the correlation is imperfect.”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“we examined the influence of sex to modify the well-characterized cross-sectional association between regional tau PET and global Aβ PET.14–16”
From Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults (2019) · cites this paper as [15]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“supports recent evidence that tau may play an early pathological role in Alzheimer’s disease129–131”
From Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) · cites this paper as [131]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression shrinkage and selection via the lasso
Tibshirani, R. (1996) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1996.tb02080.x · Cited by 51,482 · cited 2×
“The family of penalized regression fit here is the elastic net penalty (27): the L1 penalty component enforces sparsity (that is, many bs will be identically 0, not included in the model) (26), whereas the L2 penalty allows highly correlated variables to enter the model simultaneously (27).”
Regularization and Variable Selection Via the Elastic Net
Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 3×
“The specificity of this relationship strengthens the argument that the identified relationships are disease-specific: elevated tau in the CSF is associated with tau deposition within regions known to be sensitive to AD-related tauopathy (2).”
InfluentialThe Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Self-citationAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 2×
“Overlap with respect to CDR status likely represents the variable relationship between pathological burden and cognitive symptoms often attributed to differences in host factors, for example, cognitive reserve (8, 23).”
Self-citationOverdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,732
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · cited 2×
“The Aβ imaging literature has grown over the past decade (4), whereas tau imaging is a relatively new addition to the field.”
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Research works printed but not linked: 1
- 50. Roussas GG A First Course in Mathematical Statistics Addison-Wesley Pub. Co. Reading, MA 1973
Cited by
Items 201–300 of 736
P2X7-deficiency improves plasticity and cognitive abilities in a mouse model of Tauopathy
Carvalho, K., Martin, E., Cès, A., Sarrazin, N., Lagouge-Roussey, P., Nous, C., Boucherit, L., Youssef, I., Prigent, A., Faivre, É., et al. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2021.102139 · Cited by 58
Imaging in Central Nervous System Drug Discovery
Gunn, R. N., & Rabiner, E. A. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.001 · Cited by 51
Left frontal connectivity attenuates the adverse effect of entorhinal tau pathology on memory
Neitzel, J., Franzmeier, N., Rubinski, A., Ewers, M., & (ADNI), F. T. A. D. N. I. (2019) · Neurology · doi:10.1212/wnl.0000000000007822 · Cited by 49
Working Memory in Alzheimer’s Disease and Parkinson’s Disease
Zokaei, N., & Husain, M. (2019) · Current topics in behavioral neurosciences · doi:10.1007/7854_2019_103 · Cited by 57
Petersen, M. E., for the Alzheimer’s Biomarker Consortium –Down Syndrome (ABC-DS), Rafii, M. S., Zhang, F., Hall, J., Julovich, D., Ances, B. M., Schupf, N., Krinsky-McHale, S. J., Mapstone, M., et al. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-201167 · Cited by 48
Self-citationSong, M. K., Bischoff, D. S., Song, A. M., Uyemura, K., & Yamaguchi, D. T. (2016) · BBA Clinical · doi:10.1016/j.bbacli.2016.09.003 · Cited by 52
Tsai, C., Liang, C., Lee, J., Su, M., Lin, C., Chu, H., Tsai, C., Lin, G., Lin, Y., & Yang, F. (2019) · Journal of Clinical Medicine · doi:10.2139/ssrn.3464407 · Cited by 54
Chemicals used for the induction of Alzheimer’s disease-like cognitive dysfunctions in rodents
Mahdi, O., Baharuldin, M. T. H., Nor, N. H. M., Chiroma, S. M., Jagadeesan, S., & Moklas, M. A. M. (2019) · Biomedical Research and Therapy · doi:10.15419/bmrat.v6i11.575 · Cited by 62
McDonough, I. M., Festini, S. B., & Wood, M. M. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101133 · Cited by 58
Overview of therapeutic targets in management of dementia
Malik, R., Kalra, S., Bhatia, S., Al‐Harrasi, A., Singh, G., Mohan, S., Makeen, H. A., Albratty, M., Meraya, A. M., Bahar, B., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113168 · Cited by 55
Day, G. S. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001089 · Cited by 58
Abskharon, R., Pan, H., Sawaya, M. R., Seidler, P. M., Olivares, E. J., Chen, Y., Murray, K. A., Zhang, J., Lantz, C., Bentzel, M., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2300258120 · Cited by 47
Early- and Late-Onset Alzheimer’s Disease: Two Sides of the Same Coin?
Valdez-Gaxiola, C. A., Rosales-Leycegui, F., Gaxiola-Rubio, A., Moreno-Ortíz, J. M., & Figuera, L. E. (2024) · Diseases · doi:10.3390/diseases12060110 · Cited by 65
RETRACTED ARTICLE: VPS35 regulates tau phosphorylation and neuropathology in tauopathy
Vagnozzi, A. N., Li, J.-G., Chiu, J., Razmpour, R., Warfield, R., Ramirez, S. H., & Praticò, D. (2021) · Molecular Psychiatry · doi:10.1038/s41380-019-0453-x · Cited by 36
“Progressive accumulation of hyperphosphorylated and pathological conformation-changed tau inside neurons represents a central pathogenic event in AD and related tauopathies, and several studies have shown that the amount of tau pathology better correlates with neuronal dysfunction and cognitive impairments than Aβ loa…”
BackgroundRetractedThe Neuroprotective and Neurodegeneration Effects of Heme Oxygenase-1 in Alzheimer’s Disease
Si, Z., & Wang, X. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200720 · Cited by 47
Gaikwad, S., Puangmalai, N., Sonawane, M., Montalbano, M., Price, R., Iyer, M. S., Ray, A., Moreno, S., & Kayed, R. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adj5958 · Cited by 52
“Distribution of pathological tau strongly correlates with clinical severity and neurodegeneration in patients with AD ( 2 , 3 ).”
BackgroundThaker, A. A., Weinberg, B. D., Dillon, W. P., Hess, C. P., Cabral, H., Fleischman, D. A., Leurgans, S. E., Bennett, D. A., Hyman, B. T., Albert, M., et al. (2017) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5133 · Cited by 50
Overlapping Neuroimmune Mechanisms and Therapeutic Targets in Neurodegenerative Disorders
Marchi, F. D., Munitić, I., Vidatic, L., Papić, E., Rački, V., Nimac, J., Jurak, I., Novotni, G., Rogelj, B., Vuletić, V., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11102793 · Cited by 53
“Since intraneuronal aggregates of tau protein have been shown to directly correlate with cognitive decline in AD [183,184], they comprise a potentially even more interesting target than A β .”
BackgroundDeath-associated protein kinase 1 as a therapeutic target for Alzheimer's disease
Zhang, T., Kim, B. M., & Lee, T. H. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-023-00395-5 · Cited by 53
Chiaravalloti, A., Barbagallo, G., Ricci, M., Martorana, A., Ursini, F., Sannino, P., Karalis, G., & Schillaci, O. (2017) · Brain Research · doi:10.1016/j.brainres.2017.10.016 · Cited by 49
Cross-sectional associations between [18F]GTP1 tau PET and cognition in Alzheimer's disease
Teng, E., Ward, M., Manser, P. T., Sanabria-Bohorquez, S., Ray, R. D., Wildsmith, K. R., Baker, S., Kerchner, G. A., & Weimer, R. M. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.05.026 · Cited by 45
Defining and predicting transdiagnostic categories of neurodegenerative disease
Cornblath, E. J., Robinson, J. L., Irwin, D. J., Lee, E. B., Lee, V. M.-Y., Trojanowski, J. Q., & Bassett, D. S. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0593-y · Cited by 45
“[37] Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J, et al.”
BackgroundZhang, J., Wang, J., Zhou, G.-S., Tan, Y.-J., Tao, H.-J., Chen, J.-Q., Pu, Z.-J., Ma, J.-Y., She, W., Kang, A., et al. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8636835 · Cited by 44
“This was consistent with the current findings that cholinergic neuron damage was a key pathological change associated with cognitive dysfunction in AD [14].”
ResultGoodwin, M. S., Sinyavskaya, O., Burg, F., O’Neal, V., Ceballos-Diaz, C., Cruz, P. E., Lewis, J., Giasson, B. I., Davies, P., Golde, T. E., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.007 · Cited by 44
Bijari, N., Balalaie, S., Akbari, V., Golmohammadi, F., Moradi, S., Adibi, H., & Khodarahmi, R. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.08.175 · Cited by 43
Wolters, E. E., Ossenkoppele, R., Verfaillie, S. C. J., Coomans, E. M., Timmers, T., Visser, D., Tuncel, H., Golla, S. S. V., Windhorst, A. D., Boellaard, R., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04758-2 · Cited by 42
Pontecorvo, M. J., Keene, C. D., Beach, T. G., Montine, T. J., Arora, A. K., Devous, M. D., Navitsky, M., Kennedy, I., Joshi, A. D., Lu, M., et al. (2020) · EJNMMI Research · doi:10.1186/s13550-020-00653-x · Cited by 43
Self-citationGibbons, G. S., Kim, S., Wu, Q., Riddle, D. M., Leight, S. N., Changolkar, L. N., Xu, H. W., Meymand, E. S., O’Reilly, M., Zhang, B., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00404-5 · Cited by 49
[18F]-AV-1451 binding profile in chronic traumatic encephalopathy: a postmortem case series
Marquié, M., Agüero, C., Amaral, A. C. S., Villarejo‐Galende, A., Ramanan, P., Chong, M. S. T., Saez-Calveras, N., Bennett, R. E., Verwer, E. E., Kim, S. J. W., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0808-1 · Cited by 45
The A/T/N model applied through imaging biomarkers in a memory clinic
Dodich, A., Mendes, A., Assal, F., Chicherio, C., Rakotomiaramanana, B., Andryszak, P., Festari, C., Ribaldi, F., Scheffler, M., Schibli, R., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04536-9 · Cited by 44
Rombouts, F. J. R., Andrés, J.-I., Ariza, M., Alonso, J. M., Austin, N. E., Bottelbergs, A., Chen, L., Chupakhin, V., Cleiren, E., Fierens, K., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01173 · Cited by 44
Belostozky, A., Richman, M., Lisniansky, E., Tovchygrechko, A., Chill, J. H., & Rahimipour, S. (2018) · Chemical Communications · doi:10.1039/c8cc01233d · Cited by 41
Hampton, O. L., Buckley, R. F., Manning, L. K., Scott, M. R., Properzi, M. J., Peña-Gómez, C., Jacobs, H. I. L., Chhatwal, J. P., Johnson, K. A., Sperling, R. A., et al. (2020) · NeuroImage Clinical · doi:10.1016/j.nicl.2020.102407 · Cited by 47
“Additional biomarkers including tau pathology (Brier et al., 2016; Gordon et al., 2018; Jack et al., 2019; Mattsson et al., 2019; Sperling et al., 2019), neurodegeneration (Mormino et al., 2014a; Jack et al., 2019; Mattsson et al., 2019), cardiovascular risk (Vemuri et al., 2015; Rabin et al.,…”
BackgroundMemory Correlates of Alzheimer’s Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study
Reijs, B. L. R., Ramakers, I. H. G. B., Köhler, S., Teunissen, C. E., Simmelink, M. J. A., Nathan, P. J., Tsolaki, M., Wahlund, L., Waldemar, G., Hausner, L., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160766 · Cited by 47
Liu, Y., He, X., Li, Y., & Wang, T. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.122 · Cited by 41
Zhu, B., Zhang, T., Jiang, Q., Li, Y., Fu, Y., Dai, J., Li, G., Qi, Q., & Cheng, Y. (2018) · Chemical Communications · doi:10.1039/c8cc06897f · Cited by 40
Therapeutic potential of dental pulp stem cell transplantation in a rat model of Alzheimer’s disease
Zhang, X., Ouyang, Y.-J., Yu, B.-Q., Li, W., Yu, M.-Y., Li, J.-Y., Jiao, Z., Yang, D., Li, N., Shi, Y., et al. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.297088 · Cited by 43
“Aβ plaques and tau tangles interfere with neuron-to-neuron communication and neuronal nutrition, leading to neuronal death, memory loss and the abnormal behavior observed in dementia (Brier et al., 2016).”
Stem Cell Therapies in Alzheimer’s Disease: Applications for Disease Modeling
Si, Z., & Wang, X. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000324 · Cited by 46
Relationships between β-amyloid and tau in an elderly population: An accelerated failure time model
Therneau, T. M., Knopman, D. S., Lowe, V. J., Botha, H., Graff‐Radford, J., Jones, D. T., Vemuri, P., Mielke, M. M., Schwarz, C. G., Senjem, M. L., et al. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118440 · Cited by 45
“The use of ADRC participants is particularly valuable when it comes to tau PET, which is closely tied to cognition (Brier et al., 2016; Johnson et al., 2016).”
Kushwah, S., Maurya, N. S., Kushwaha, S. K., Scotti, L., Chawade, A., & Mani, A. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230216094353 · Cited by 50
Zhang, Y., Liu, X., Wiggins, K. L., Kurniansyah, N., Guo, X., Rodrigue, A., Zhao, W., Yanek, L. R., Ratliff, S. M., Pitsillides, A., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207157 · Cited by 44
Smith, C. J., Ashford, J. W., & Perfetti, T. A. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181089 · Cited by 43
Regional vulnerability and spreading of hyperphosphorylated tau in seeded mouse brain
Detrez, J. R., Maurin, H., Van Kolen, K., Willems, R., Colombelli, J., Lechat, B., Roucourt, B., Van Leuven, F., Baatout, S., Larsen, P., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.03.010 · Cited by 39
“While the triggers for the initial tau hyperphosphorylation and aggregation process remain elusive, tau pathology appears to follow a stereotypical spreading pattern in the affected brain (Brier et al., 2016).”
BackgroundPereira, J. B., Harrison, T. M., La Joie, R., Baker, S. L., & Jagust, W. J. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04669-x · Cited by 39
Lo, A. C., Evans, C. D., Mancini, M., Wang, H., Shcherbinin, S., Lu, M., Natanegara, F., & Willis, B. A. (2021) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-210296 · Cited by 39
Avelar‐Pereira, B., Belloy, M. E., O'Hara, R. M., Hosseini, S. M. H., & Initiative, A. D. N. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01886-z · Cited by 51
Recent Advances: Decoding Alzheimer’s Disease With Stem Cells
Fang, Y., Gao, T., Zhang, B., & Pu, J. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00077 · Cited by 42
“and tau predicts dementia symptoms better than Aβ (Brier et al., 2016).”
BackgroundAssessment of Alzheimer’s Disease Based on Texture Analysis of the Entorhinal Cortex
Leandrou, S., Lamnisos, D., Mamais, I., Kyriacou, P. A., Pattichis, C. S., & Initiative, A. D. N. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00176 · Cited by 46
“…as seen in positron emission tomography (PET) (Mosconi et al., 2008), positivity on amyloid imaging as seen in PET (Johnson et al., 2013), and abnormal neuronal cerebrospinal fluid (CSF) biomarkers (tau and/or A β ) (Brier et al., 2016; Bjerke and Engelborghs, 2018; Blennow and Zetterberg, 2018).”
BackgroundRetromer regulates the lysosomal clearance of MAPT/tau
Carosi, J. M., Hein, L. K., van den Hurk, M., Adams, R., Milky, B., Singh, S., Bardy, C., Denton, D., Kumar, S., & Sargeant, T. J. (2021) · Autophagy · doi:10.1080/15548627.2020.1821545 · Cited by 38
P450 Eicosanoids and Reactive Oxygen Species Interplay in Brain Injury and Neuroprotection
Liu, X., Davis, C. M., & Alkayed, N. J. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7056 · Cited by 38
Modeling Alzheimer’s disease with human iPS cells: advancements, lessons, and applications
Essayan-Perez, S., Zhou, B., Nabet, A. M., Wernig, M., & Huang, Y. A. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104503 · Cited by 45
“As compared to amyloid plaques, neurofibrillary tangles correlate better with the severity of symptoms and cognitive impairment (Brier et al., 2016), suggesting that hyperphosphorylated tau plays a crucial role.”
BackgroundDevous, M. D., Fleisher, A., Pontecorvo, M. J., Lu, M., Siderowf, A. D., Navitsky, M. A., Kennedy, I. A., Southekal, S. S., Harris, T. S., & Mintun, M. A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-200808 · Cited by 45
Cellular Senescence as the Key Intermediate in Tau-Mediated Neurodegeneration
Mendelsohn, A. R., & Larrick, J. W. (2018) · Rejuvenation Research · doi:10.1089/rej.2018.2155 · Cited by 37
Role of Microglia in Regulating Cholesterol and Tau Pathology in Alzheimer’s Disease
Nanjundaiah, S., Chidambaram, H., Chandrashekar, M., & Chinnathambi, S. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00883-6 · Cited by 36
Plasma phosphorylated tau181 predicts cognitive and functional decline
Tropea, T. F., Waligórska, T., Xie, S. X., Nasrallah, I. M., Cousins, K. A. Q., Trojanowski, J. Q., Grossman, M., Irwin, D. J., Weintraub, D. A., Lee, E. B., et al. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51695 · Cited by 40
Imaging of glia activation in people with primary lateral sclerosis
Paganoni, S., Alshikho, M. J., Zürcher, N. R., Cernasov, P., Babu, S., Loggia, M. L., Chan, J. G. M., Chonde, D. B., Izquierdo‐Garcia, D., Catana, C., et al. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.10.024 · Cited by 36
“…represents the first step in the development of [11C]-PBR28 PET as an in vivo PLS biomarker, an approach that is aligned with efforts that are unfolding in other neurologic diseases (Coughlin et al., 2017; Brier et al., 2016; Passamonti et al., 2017; Gomperts et al., 2016; Herranz et al., 2016).”
Memory concerns in the early Alzheimer's disease prodrome: Regional association with tau deposition
Swinford, C. G., Risacher, S. L., Charil, A., Schwarz, A. J., Saykin, A. J., & Initiative, A. D. N. (2018) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.03.001 · Cited by 36
Hyperexcitability and seizures in the THY-Tau22 mouse model of tauopathy
Gómez‐Murcia, V., Sandau, U. S., Ferry, B., Parrot, S., Laurent, C., Basquin, M., Buée, L., Boison, D., & Blum, D. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.06.004 · Cited by 39
“Topographical spread of Tau pathology has been linked to progressive cognitive deterioration (Bejanin et al., 2017; Brier et al., 2016; Colin et al., 2020; Duyckaerts et al. 1997).”
BackgroundJablonski, A. M., Warren, L., Usenovic, M., Zhou, H., Sugam, J., Parmentier-Batteur, S., & Voleti, B. (2021) · Scientific Reports · doi:10.1038/s41598-021-82901-1 · Cited by 36
Bos, I., Vos, S. J. B., Jansen, W. J., Vandenberghe, R. R., Gabel, S., Estanga, A., Ecay‐Torres, M., Tomassen, J., den Braber, A., Lleó, A., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00193 · Cited by 41
“…other neurodegenerative features, rather than Aβ, are associated with cognitive impairment and decline in various cognitive domains (Nelson et al., 2012; Mormino et al., 2014; Pettigrew et al., 2015; Brier et al., 2016; Degerman Gunnarsson et al., 2016; Dumurgier et al., 2017; Cerami et al., 2018).”
BackgroundAllison, S. L., Rodebaugh, T. L., Johnston, C., Fagan, A. M., Morris, J. C., & Head, D. M. (2019) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acz019 · Cited by 44
Self-citationUsnic acid derivatives as tau-aggregation and neuroinflammation inhibitors
Shi, C., Peng, W., Zhao, J., Yang, H., Qu, L., Wang, C., Kong, L., & Wang, X. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111961 · Cited by 36
Selective Neuron Vulnerability in Common and Rare Diseases—Mitochondria in the Focus
Paß, T., Wiesner, R. J., & Pla‐Martín, D. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.676187 · Cited by 39
Barthélemy, N. R., Toth, B., Manser, P. T., Bohorquez, S. M. S., Teng, E., Keeley, M., Bateman, R. J., Weimer, R. M., & Wildsmith, K. R. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210677 · Cited by 36
A multi-scale model explains oscillatory slowing and neuronal hyperactivity in Alzheimer’s disease
Alexandersen, C. G., de Haan, W., Bick, C., & Goriely, A. (2023) · Journal of The Royal Society Interface · doi:10.1098/rsif.2022.0607 · Cited by 39
Kunkle, B., Grenier-Boley, B., Sims, R., Bis, J., Naj, A., Boland, A., Vronskaya, M., van der Lee, S., Amlie-Wolf, A., Bellenguez, C., et al. (2018) · doi:10.1101/294629 · Cited by 35
Self-citationRetinal ganglion cell vulnerability to pathogenic tau in Alzheimer’s disease
Davis, M. R., Robinson, E., Koronyo, Y., Salobrar‐García, E., Rentsendorj, A., Gaire, B. P., Mirzaei, N., Kayed, R., Sadun, A. A., Ljubimov, A. V., et al. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-01935-y · Cited by 37
Maphis, N. M., Jiang, S., Binder, J., Wright, C., Gopalan, B., Lamb, B. T., & Bhaskar, K. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00069 · Cited by 35
“A growing number of studies implicate reasonably significant positive correlations between the build-up of NFTs and cognitive impairment in various tau-targeted imaging studies in humans (Nelson et al., 2012; Murray et al., 2015; Brier et al., 2016; Ossenkoppele et al., 2016; Scholl et al., 2016).”
BackgroundKrance, S. H., Cogo‐Moreira, H., Rabin, J. S., Black, S. E., & Swardfager, W. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.1056-19.2019 · Cited by 36
“Too few longitudinal AV-1451 PET measures were available to model in ADNI cohorts, precluding exploration of tau deposition dynamics and regional specificity in brain; however, CSF p-tau appears to correlate with tau deposition (Brier et al., 2016), making CSF p-tau a reasonable proxy of pathologic tau for the present…”
BackgroundMethodComparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease
Dincer, A., Gordon, B. A., Hari-Raj, A., Keefe, S. J., Flores, S., McKay, N. S., Paulick, A. M., Shady Lewis, K. E., Feldman, R. L., Hornbeck, R. C., et al. (2020) · NeuroImage: Clinical · doi:10.1016/j.nicl.2020.102491 · Cited by 34
Self-citationAPOE ε4 genotype, amyloid-β, and sex interact to predict tau in regions of high APOE mRNA expression
Dincer, A., Chen, C. D., McKay, N. S., Koenig, L. N., McCullough, A. A., Flores, S. E., Keefe, S., Schultz, S. A., Feldman, R. L., Joseph‐Mathurin, N., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl7646 · Cited by 40
Self-citationTau Imaging in Alzheimer's Disease Diagnosis and Clinical Trials
Brosch, J. R., Farlow, M. R., Risacher, S. L., & Apostolova, L. G. (2016) · Neurotherapeutics · doi:10.1007/s13311-016-0490-y · Cited by 40
Free Heme and Amyloid-β: A Fatal Liaison in Alzheimer’s Disease
Chiziane, E., Telemann, H., Krueger, M., Adler, J., Arnhold, J., Alia, A., & Flemmig, J. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170711 · Cited by 33
In vivo coupling of tau pathology and cortical thinning in Alzheimer's disease
Mak, E., Bethlehem, R. A. I., Romero-García, R., Červenka, S., Rittman, T., Gabel, S., Surendranathan, A., Bevan-Jones, W. R., Passamonti, L., Rodríguez, P. V., et al. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.08.005 · Cited by 38
Level of education mitigates the impact of tau pathology on neuronal function
Initiative, A. D. N., Hoenig, M. C., Bischof, G. N., Onur, O. A., Kukolja, J., Jessen, F., Fließbach, K., Neumaier, B., Fink, G. R., Kalbe, E., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04342-3 · Cited by 38
“…processes, tau pathology, in contrast to A β pathology, is more closely associated with neuronal dysfunction [2, 3] and symptom severity [4, 5] in individuals with typical AD and variants of AD such as posterior cortical atrophy, the logopenic variant and the behavioural variant [2, 6,…”
Kumar, D., Sharma, A., & Sharma, L. K. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200203101828 · Cited by 38
Rodríguez-Lavado, J., Gallardo‐Garrido, C., Mallea, M., Bustos, V., Osorio, R., Hödar-Salazar, M., Chung, H., Araya‐Maturana, R., Lorca, M., Pessoa-Mahana, C. D., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112368 · Cited by 34
ASAF: altered spontaneous activity fingerprinting in Alzheimer’s disease based on multisite fMRI
Li, J., Jin, D., Li, A., Liu, B., Song, C., Wang, P., Wang, D., Xu, K., Yang, H., Yao, H., et al. (2019) · 中国科学通报:英文版 · doi:10.1016/j.scib.2019.04.034 · Cited by 36
Marquez, A., Guernsey, L. S., Frizzi, K. E., Cundiff, M., Constantino, I., Muttalib, N., Arenas, F., Zhou, X., Lim, S. H., Ferdousi, M., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105273 · Cited by 36
“PET imaging studies have shown that cognition correlates better with tau pathology than with Aβ plaque deposition (Brier et al., 2016; Johnson et al., 2016), suggesting that tau pathology likely contributes to cognitive decline in AD, * Corresponding author at: 9500 Gilman Drive, La Jolla, CA…”
BackgroundPsychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms
Garcia‐Romeu, A., Darcy, S., Jackson, H., White, T., & Rosenberg, P. B. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_267 · Cited by 36
“PET is a critical tool for understanding and diagnosing AD, allowing Aβ and tau deposition to be evaluated in vivo (Brier et al. 2016), and using ligands such as fluorodeoxyglucose (FDG) to assess functional brain metabolism (Rice and Bisdas 2017).”
BackgroundMethodYoshikawa, M., Soeda, Y., Michikawa, M., Almeida, O. F. X., & Takashima, A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00124 · Cited by 33
“, 2017) and in AD patients (Brier et al., 2016) better than Aβ.”
BackgroundResultInfluentialAbskharon, R. N. N., Seidler, P. M., Sawaya, M. R., Cascio, D., Yang, T. P., Philipp, S., Williams, C. K., Newell, K. L., Ghetti, B. F., Deture, M. A., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013638 · Cited by 33
Selective neuronal vulnerability in Alzheimer’s disease: a network-based analysisPreprint
Roussarie, J.-P., Yao, V., Plautz, Z., Kasturia, S. E., Albornoz, C. A., Schmidt, E. F., Brichta, L., Barnea-Cramer, A. O., Heintz, N., Hof, P. R., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/499897 · Cited by 31
Shi, H., Mirzaei, N., Koronyo, Y., Davis, M. R., Robinson, E., Braun, G. M., Jallow, O., Rentsendorj, A., Ramanujan, V. K., Fert‐Bober, J., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02760-8 · Cited by 35
Antigen-specific age-related memory CD8 T cells induce and track Alzheimer’s-like neurodegeneration
Panwar, A., Rentsendorj, A., Jhun, M., Cohen, R. M., Cordner, R., Gull, N., Pechnick, R. N., Duvall, G., Mardiros, A., Golchian, D., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2401420121 · Cited by 40
Molecular Insights Into Memory-Enhancing Metabolites of Nicotine in Brain: A Systematic Review
Majdi, A., Kamari, F., Sadigh‐Eteghad, S., & GJEDDE, A. H. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01002 · Cited by 34
“Tau accumulation in the temporal lobe correlates better with cognitive dysfunction than Aβ deposition in any region of the brain (Brier et al., 2016).”
BackgroundYu, L., Petyuk, V., Tasaki, S., Boyle, P. A., Gaiteri, C., Schneider, J. A., Jager, P. L. D., & Bennett, D. A. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.0834 · Cited by 32
Relationship between tau, neuroinflammation and atrophy in Alzheimer's disease: The NIMROD study
Su, L., Surendranathan, A., Huang, Y., Bevan-Jones, W. R., Passamonti, L., Hong, Y. T., Arnold, R., Rodríguez, P. V., Wang, Y., Mak, E., et al. (2021) · Information Fusion · doi:10.1016/j.inffus.2020.10.006 · Cited by 30
Early alterations of neurovascular unit in the retina in mouse models of tauopathy
Xia, F., Ha, Y., Shi, S., Li, Y., Li, S., Luisi, J. D., Kayed, R., Motamedi, M., Liu, H., & Zhang, W. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01149-y · Cited by 33
Elevated medial temporal lobe and pervasive brain tau‐PET signal in normal participants
Lowe, V. J., Bruinsma, T. J., Min, H.-K. P., Lundt, E. S., Fang, P., Senjem, M. L., Boeve, B. F., Josephs, K. A., Pandey, M. K., Murray, M. E., et al. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.01.005 · Cited by 34
Etekochay, M. O., Amaravadhi, A. R., González, G. V., Atanasov, A. G., Matin, M., Mofatteh, M., Steinbusch, H. W. M., Tesfaye, T., & Praticò, D. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231135 · Cited by 34
Beta amyloid deposition maps onto hippocampal and subiculum atrophy in dementia with Lewy bodies
Mak, E., Donaghy, P. C., McKiernan, E., Firbank, M. J., Lloyd, J., Petrides, G. S., Thomas, A. J., & O'Brien, J. T. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.09.004 · Cited by 29
Smith, G. S., Workman, C. I., Protas, H. D., Su, Y., Savonenko, A. V., Kuwabara, H., Gould, N. F., Kraut, M. A., Joo, J. H., Nandi, A., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01539-9 · Cited by 34
Self-citationMulticenter 18F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer’s Disease
Rullmann, M., Brendel, M., Schroeter, M. L., Saur, D., Levin, J., Perneczky, R. G., Tiepolt, S., Patt, M., Mueller, A., Villemagne, V. L., et al. (2022) · Biomolecules · doi:10.3390/biom12030458 · Cited by 29
“Also other groups report age effects at least in the medial temporal lobe [29,30], but there are also studies, which found no age association with tau PET signal [8,31].”
BackgroundFunctional Connectivity Dynamics Altered of the Resting Brain in Subjective Cognitive Decline
Wei, Y., Kung, Y., Huang, W., Lin, C., Chen, Y.-L., Chen, C., Shyu, Y., & Lin, C. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.817137 · Cited by 31
“, 2019) and is a good tracer of disease progression (Brier et al., 2016).”
BackgroundSynthesizing images of tau pathology from cross-modal neuroimaging using deep learning
Lee, J., Burkett, B. J., Min, H.-K. P., Senjem, M. L., Dicks, E., Corriveau‐Lecavalier, N., Mester, C. T., Wiste, H. J., Lundt, E. S., Murray, M. E., et al. (2023) · Brain · doi:10.1093/brain/awad346 · Cited by 43
“Tau burden has been correlated to regions of FDG hypometabolism, 8,15,24,25 cortical atrophy 10,13,26,27 and amyloid accumulation, 26,28-30 although the correlation values are limited given the complex relationship between the biomarkers.”
BackgroundBurnham, S. C., Iaccarino, L., Pontecorvo, M. J., Fleisher, A., Lu, M., Collins, E. C., & Devous, M. D. (2023) · Brain Communications · doi:10.1093/braincomms/fcad305 · Cited by 36
“Much of the published literature 10-28 indicates that the binding of flortaucipir to tau NFTs parallels NFT accumulation described as Braak stages, 10,29-31 especially for A β -positive subjects, 30,32 and correlates with clinical symptoms and measures of neurodegeneration.”
BackgroundResultInfluentialVanderlip, C. R., Stark, C. E. L., & Initiative, A. D. N. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14154 · Cited by 27
“48,49 53 While the mechanism by which this happens is not fully understood, it has been suggested that hippocampal hyperexcitability may be the mediating factor.”
Default mode network tau predicts future clinical decline in atypical early Alzheimer’s disease
Katsumi, Y., Howe, I., Eckbo, R., Wong, B., Quimby, M., Hochberg, D., McGinnis, S. M., Putcha, D., Wolk, D. A., Touroutoglou, A., et al. (2024) · Brain · doi:10.1093/brain/awae327 · Cited by 32
Llibre-Guerra, J. J., Fernandez, M. V., Joseph-Mathurin, N., Bian, S., Carter, K., Li, Y., Aschenbrenner, A. J., Pottier, C., Sigurdson, W., McDade, E., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03494-0 · Cited by 28
“An additional questionnaire exploring medical history and exposome factors included multipurpose health surveys from the National Health and Nutrition Examination Survey (wwwn.cdc.gov/nchs/nhanes/) 36 .”
Self-citation
Metadata
- Authors
- Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., Cairns, N. J., Holtzman, D. M., Fagan, A. M., Morris, J. C., Benzinger, T. L. S., & Ances, B. M.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Benzinger, Tammie L. S.
- Ances, Beau M.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-05-11
- Volume
- 8
- Issue
- 338
- Pages
- 338ra66-338ra66
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5267531
- OpenAlex
- W2353776455
- Cited by
- 734
- References
- 56
- Citations by year
- 2026: 40 · 2025: 60 · 2024: 58 · 2023: 69 · 2022: 64 · 2021: 90 · 2020: 101 · 2019: 80 · 2018: 73 · 2017: 75 · 2016: 23
- FWCI
- 74.35
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion, cc-by)
- PubMed Central (acceptedVersion, cc-by)
- Open Scholarship Institutional Repository (Washington University in St. Louis) (submittedVersion)
- Funders
- NIH (P50AG05681, P01AG003991, P01AG026276, 5P30NS048056, 2UL1TR000448, 5RO1AG04343404)
- NSF (DMS1300280)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, tau PET imaging, cerebrospinal fluid tau, temporal lobe, preclinical Alzheimer's disease, cognitive performance, disease progression, neurofibrillary tangles, neuritic plaques
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Cognition, Female, Humans, Male, Peptide Fragments, Amyloid beta-Peptides, tau Proteins, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.